Genes, p53

• 

  Subject Areas on Research

  • 172G>T variant in the 5' untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. 
  • A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. 
  • A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. 
  • A new assay to quantify in vivo repair of G:T mispairs by base excision repair. 
  • A novel functional DEC1 promoter polymorphism -249T>C reduces risk of squamous cell carcinoma of the head and neck. 
  • A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. 
  • ATM Paradoxically Promotes Oncogenic Transformation via Transcriptional Reprogramming. 
  • Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. 
  • Abrogation of P53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumour cells to ionizing radiation. 
  • Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. 
  • Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. 
  • Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. 
  • Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. 
  • Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. 
  • Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. 
  • Alterations of the TP53 gene in human gliomas. 
  • An animal model of MYC-driven medulloblastoma. 
  • Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. 
  • Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. 
  • Apoptosis in haematological malignancies. 
  • Apoptosis: inhibitor or instigator of carcinogenesis? 
  • Artifactual frame-shift p53 mutation at codon 249 detected with the Cyclist DNA sequencing method. 
  • Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer. 
  • Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. 
  • Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. 
  • Aurora Kinase A is critical for the Nkx6.1 mediated β-cell proliferation pathway. 
  • C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. 
  • Characterization of human Gadd45, a p53-regulated protein. 
  • Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. 
  • Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. 
  • Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. 
  • Clonality of combined tumors. 
  • Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. 
  • Combined effects of the p53 and p73 polymorphisms on lung cancer risk. 
  • Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. 
  • Combined p53-related genetic variants together with HPV infection increase oral cancer risk. 
  • Comprehensive molecular portraits of human breast tumours. 
  • Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. 
  • Compromised HOXA5 function can limit p53 expression in human breast tumours. 
  • Control of G1 arrest after DNA damage. 
  • Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. 
  • DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. 
  • DNA repair and epidemiology of basal cell carcinoma. 
  • Detecting colorectal cancer in stool with the use of multiple genetic targets. 
  • Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. 
  • Dietary methionine influences therapy in mouse cancer models and alters human metabolism. 
  • Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution. 
  • Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients. 
  • Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. 
  • Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. 
  • Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. 
  • Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. 
  • Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. 
  • Experimental models of human carcinogenesis. 
  • Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. 
  • FAS Death Receptor: A Breast Cancer Subtype-Specific Radiation Response Biomarker and Potential Therapeutic Target. 
  • Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. 
  • Fragments of ATM which have dominant-negative or complementing activity. 
  • Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer. 
  • Genetic changes in contralateral bronchioloalveolar carcinomas of the lung. 
  • Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck. 
  • Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck. 
  • Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. 
  • Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. 
  • Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. 
  • Growth factor modulation of p53-mediated growth arrest versus apoptosis. 
  • High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6. 
  • Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. 
  • Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. 
  • Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. 
  • Identification and functional characterization of the human glutathione S-transferase P1 gene as a novel transcriptional target of the p53 tumor suppressor gene. 
  • Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. 
  • Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. 
  • Immunohistochemical expression of mutant p53 oncogene in transitional mucosa adjacent to human colon cancer. 
  • Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. 
  • Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. 
  • Infrequent p53 gene mutations in medulloblastomas. 
  • Inhibiting effect of murine double minute-2 oncogene on apoptosis induced by retroviral-mediated wild-type p53. 
  • Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. 
  • Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. 
  • Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: a novel transgenic mouse model of breast cancer. 
  • Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. 
  • Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. 
  • Large scale isolation of genes as DNA fragment lengths by continuous elution electrophoresis through an agarose matrix. 
  • Latitude may modify the effect of TP53 codon 72 polymorphism on cancer risk. 
  • Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. 
  • Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. 
  • Long-term cellular effects in humans chronically exposed to ionizing radiation. 
  • Loss of KAI1 expression in the progression of colorectal cancer. 
  • Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. 
  • Loss of atm radiosensitizes multiple p53 null tissues. 
  • Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. 
  • Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. 
  • Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. 
  • Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. 
  • Malignant transformation of ovarian epithelium. 
  • Mapping of peroxyl radical induced damage on genomic DNA. 
  • Mapping oxidative DNA damage at nucleotide level. 
  • Measurement of oxidative DNA damage in the human p53 and PGK1 gene at nucleotide resolution. 
  • Methodological remarks concerning the recent meta-analysis on p53 codon 72 polymorphism and colorectal cancer risk. 
  • Modulation of oncogene and tumor suppressor gene expression in a hamster model of chronic lung injury with varying degrees of pulmonary neuroendocrine cell hyperplasia. 
  • Molecular basis of endometrial cancer. 
  • Molecular biology of esophageal cancer. 
  • Molecular genetic and immunohistochemical analysis of the tumor suppressor genes Rb and p53 in palmar and aggressive fibromatosis. 
  • Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. 
  • Morphologic and molecular genetic aspects of oligodendroglial neoplasms. 
  • Multiple signaling pathways involving ATM. 
  • Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. 
  • Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. 
  • Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. 
  • Mutation of p53 gene in hepatocellular carcinoma cell lines with HBX DNA. 
  • Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. 
  • N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines. 
  • Needle-in-a-haystack detection and identification of base substitution mutations in human tissues. 
  • Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. 
  • Oncogenic base substitution mutations in circulating leukocytes of normal individuals. 
  • Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. 
  • Overexpression and mutation of p53 in endometrial carcinoma. 
  • Overexpression and mutation of p53 in epithelial ovarian cancer. 
  • Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. 
  • Overview of genetic and molecular events in the pathogenesis of lung cancer. 
  • P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. 
  • P53, cell cycle control and apoptosis: implications for cancer. 
  • P53: a determinant of the cell cycle response to DNA damage. 
  • PTEN gene mutations are seen in high-grade but not in low-grade gliomas. 
  • Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events. 
  • Participation of p53 protein in the cellular response to DNA damage. 
  • Polymorphisms of DNA repair genes and risk of glioma. 
  • Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. 
  • Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. 
  • Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. 
  • Prevalence and spectrum of p53 mutations associated with smoking in breast cancer. 
  • Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. 
  • Prognostic factors in resectable pancreatic cancer: p53 and bcl-2. 
  • Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. 
  • Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. 
  • Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. 
  • RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. 
  • Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. 
  • Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. 
  • Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. 
  • Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. 
  • Relation between p53 overexpression and established prognostic factors in breast cancer. 
  • Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. 
  • Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. 
  • Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. 
  • Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. 
  • Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis. 
  • Separate pathways for p53 induction by ionizing radiation and N-(phosphonoacetyl)-L-aspartate. 
  • Signalling to p53: where does it all start? 
  • Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. 
  • Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis. 
  • Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. 
  • Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. 
  • TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. 
  • TP53 dysfunction in diffuse large B-cell lymphoma. 
  • TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. 
  • Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. 
  • The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. 
  • The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. 
  • The p53 tumor suppressor gene frequently is altered in gynecologic cancers. 
  • The role of p53 in cell-cycle control and apoptosis: implications for cancer. 
  • The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? 
  • Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. 
  • Tp53 Suppression Promotes Cardiomyocyte Proliferation during Zebrafish Heart Regeneration. 
  • Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. 
  • Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. 
  • Tumor-suppressor p53: implications for tumor development and prognosis. 
  • Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts. 
  • Twenty-year survival in glioblastoma: a case report and molecular profile. 
  • Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist. 
  • WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. 
  • Wild-type p53 is a cell cycle checkpoint determinant following irradiation. 
  • Wild-type p53: tumors can't stand it. 
  • [Apoptosis induced by adenovirus-mediated wild-type p53 expression in human pancreatic cancer cells]. 
  • [Murine Doube Minute 2 oncogene inhibited apoptosis induced by retroviral-mediated wild-type p53]. 
  • [Studies on MDM2 oncogene expression and its effect on pancreatic carcinoma cells]. 
  • [The effect of adenovirus-mediated wild-type p53 expression on the growth of human pancreatic carcinoma cell line cells]. 
  • p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein. 
  • p53 alterations in all stages of breast cancer. 
  • p53 and ATM: cell cycle, cell death, and cancer. 
  • p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. 
  • p53 gene alterations in human prostate carcinoma. 
  • p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. 
  • p53 gene mutation spectrum in human unknown primary tumors. 
  • p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. 
  • p53 status in spontaneous and dimethylnitrosamine-induced renal cell tumors from rats. 
  • p53-based gene therapy of ovarian cancer: magic bullet? 
  • p53-dependent induction of heat shock protein 27 (HSP27) expression. 
  • p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Buckley, Anne Frances, Assistant Professor of Pathology, Pathology
  • Clyde, Merlise, Professor of Statistical Science, Statistical Science
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute